Document

August 5, 2020

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, DC 20549-3720

Attention: Abby Adams


Re:	Lumos Pharma, Inc.

Registration Statement on Form S-3

Filed July 28, 2020

File No. 333-240149

Acceleration Request

Requested Date: August 7, 2020

Requested Time: 4:00 P.M. Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Lumos Pharma, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-240149) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Rob Suffoletta at (512) 338-5439 or via email at rsuffoletta@wsgr.com.

[Signature page follows]

Securities and Exchange Commission

August 5, 2020

Page 2

Sincerely,

LUMOS PHARMA, Inc.

/s/ Richard J. Hawkins

Richard J. Hawkins

Chief Executive Officer


cc:	Bradley J. Powers, General Counsel, Lumos Pharma, Inc.

J. Robert Suffoletta, Wilson Sonsini Goodrich & Rosati, P.C.